211 related articles for article (PubMed ID: 22570868)
1. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo.
Arai R; Tsuda M; Watanabe T; Ose T; Obuse C; Maenaka K; Minami A; Ohba Y
Eur J Cancer; 2012 Oct; 48(15):2417-30. PubMed ID: 22244830
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
5. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
6. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
[TBL] [Abstract][Full Text] [Related]
7. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner.
Cicha I; Zitzmann R; Goppelt-Struebe M
Int J Biochem Cell Biol; 2014 Jan; 46():39-48. PubMed ID: 24275091
[TBL] [Abstract][Full Text] [Related]
13. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.
Choi YL; Bocanegra M; Kwon MJ; Shin YK; Nam SJ; Yang JH; Kao J; Godwin AK; Pollack JR
Cancer Res; 2010 Mar; 70(6):2296-306. PubMed ID: 20215510
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
Bartscht T; Lehnert H; Gieseler F; Ungefroren H
Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Src activation with cardiotoxin III blocks migration and invasion of MDA-MB-231 cells.
Tsai PC; Chu CL; Chiu CC; Chang LS; Lin SR
Toxicon; 2013 Nov; 74():56-67. PubMed ID: 23933586
[TBL] [Abstract][Full Text] [Related]
17. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
18. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation.
Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS
Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]